Finally, Maviret, AbbVie’s hepatitis C drug, has made it through Canada’s approval process and has been listed for coverage by Ontario’s PharmaCare. We hope BC PharmaCare will also list it soon.
- “MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)…
- MAVIRET™ is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease”
See HepCBC’s patient-group recommendations about Maviret to CADTH and BC PharmaCare in 2017:
- MAVIRET™ (glecaprevir + pibrentasvir) – HCV – Canada (CADTH)
- MAVIRET™ (glecaprevir + pibrentasvir) – HCV – BC (PharmaCare)